By Kelly Cloonan
Beyond Air has secured a patent for its treatment of non-tuberculous mycobacteria lung infections using gaseous nitric oxide.
The medical device and biopharmaceutical company said Thursday the patent will expire in 2038.
Chief Executive Steve Lisi said the patent strengthens the company's intellectual property portfolio and reinforces the potential of its LungFit program.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 24, 2025 17:23 ET (21:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.